Dominic Muston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9515875/publications.pdf

Version: 2024-02-01

933447 940533 1,029 19 10 16 citations h-index g-index papers 20 20 20 1116 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. European Urology, 2008, 54, 543-562.	1.9	676
2	A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. British Journal of Cancer, 2006, 94, 1361-1368.	6.4	131
3	Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thrombosis Journal, 2015, 13, 20.	2.1	37
4	Cost Effectiveness of CT Colonography for UK NHS Colorectal Cancer Screening of Asymptomatic Adults Aged 60–69 Years. Applied Health Economics and Health Policy, 2010, 8, 141-154.	2.1	33
5	A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthalmologica, 2018, 96, e942-e949.	1.1	28
6	Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmology, 2015, 15, 52.	1.4	26
7	An economic evaluation of topical treatments for actinic keratosis. Journal of Dermatological Treatment, 2009, 20, 266-275.	2.2	25
8	Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecologic Oncology, 2020, 159, 491-497.	1.4	16
9	Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model. BMC Cancer, 2014, 14, 364.	2.6	15
10	Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies., 2017, 58, 4818.		14
11	An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data. BMC Ophthalmology, 2018, 18, 340.	1.4	10
12	Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). Targeted Oncology, 2021, 16, 613-623.	3.6	6
13	A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Pharmacoeconomics, 2020, 38, 1201-1218.	3.3	5
14	Association between time to first subsequent therapy (TFST) and overall survival (OS) in previously untreated patients with ovarian cancer (OC): A SEER Medicare database analysis Journal of Clinical Oncology, 2019, 37, e17095-e17095.	1.6	3
15	Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. Journal of Market Access & Health Policy, 2022, 10, .	1.5	2
16	PHP82 USE OF INDIRECT COMPARISON IN HTA SUBMISSIONS. Value in Health, 2009, 12, A93-A94.	0.3	1
17	Cost of Illness, Diagnosis and treatment patterns for Diabetic Macular Edema across 13 Countries. Value in Health, 2015, 18, A181.	0.3	1
18	PMC63 SYSTEMATIC REVIEW RELIABILITY: SENSITIVITY AND SPECIFICITY OF ONEVS.TWO REVIEWS. Value in Health, 2008, 11, A578-A579.	0.3	0

#	Article	IF	CITATIONS
19	Olaparib in combination with bevacizumab compared to bevacizumab monotherapy for the first-line maintenance treatment of advanced ovarian cancer: a cost-effectiveness analysis. Gynecologic Oncology, 2021, 162, S216-S217.	1.4	0